PTGX
Protagonist Therapeutics Inc
141.90$
+3.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 19.3% | -161.5% | -17,977.1% | -253.2% | -394.3% | -406.8% | -117.1% | 42.4% | 125.3% | |
| – | – | – | 2.0% | 1.7% | 1,080.1% | 9.0% | 10.1% | 12.7% | 5.5% | 0.7% | 2.8% | |
| – | – | – | 21.1% | 22.4% | 3,616.0% | 27.6% | 59.9% | 91.0% | 48.8% | 8.6% | 99.9% | |
| – | – | – | 24.3% | 22.4% | 3,619.5% | 29.6% | 66.2% | 91.0% | – | – | – | |
| – | – | – | 177.2% | -58.3% | 11,317.7% | -66.4% | -12.1% | -29.2% | -32.5% | -28.2% | 317.7% | |
| – | – | – | 3.3% | 1.6% | 418.6% | 1.6% | 4.0% | 3.0% | 1.0% | 0.3% | 3.5% | |
| – | – | – | 78.9% | 7.2% | -23,251.1% | -317.7% | -58.0% | 344.1% | -65.4% | -68.9% | -107.2% | |
| – | – | – | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | – | 326.7% | 7.9% | 15,701.7% | 754.9% | -0.7% | -0.7% | -1.3% | – | – | |
| – | – | – | 48.7% | 31.6% | 4,227.3% | 110.1% | 0.0% | 54.7% | – | – | – | |
| – | – | – | 326.7% | 78.0% | 19,929.0% | 865.0% | 474.9% | 70.9% | 284.1% | 6.0% | 49.7% | |
| – | – | – | 425.6% | -76.9% | -21,310.4% | 294.6% | 22.2% | 7.8% | 101.6% | -20.6% | 67.7% | |
| – | – | – | 16.0% | -163.1% | -18,395.7% | -254.8% | -398.3% | -409.8% | -118.1% | 42.1% | 121.9% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.